LEXINGTON, Mass., July 29, 2015 /CNW/ -- Pulmatrix, Inc., (NASDAQ: PULM) will webcast an investor presentation August 6, 2015 at 10:45 am EDT. As part of the presentation, Robert Clarke, Chief Executive Officer, will review Pulmatrix's strategic plan and provide an update on the Company's pipeline of inhaled therapeutics based on their proprietary iSPERSE™ inhaled dry powder technology.
Date: Thursday, August 6, 2015
Time: 10:45 am EDT
Link: http://ir.pulmatrix.com (select link under 'Events')
The presentation will be a live, interactive online event where investors are invited to ask the company questions in real-time. An archived presentation and online investor resource page will be available for 90 days. It is recommended that investors pre-register to save time and receive event updates. Learn more about the event at http://VirtualInvestorConferences.com
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis (CF), as well as PUR1500, an inhaled product for the treatment of idiopathic pulmonary fibrosis. In addition, Pulmatrix intends to pursue opportunities in major pulmonary diseases through collaborations, which includes PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease (COPD) in partnership with Mylan N.V. Pulmatrix's product candidates are based on iSPERSE™, its proprietary dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.
SOURCE Pulmatrix, Inc.